Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 16/20 | 0.87 |
| ▸ | INSR | P06213 | 14/20 | 0.87 |
| ▸ | IGF1R | P08069 | 13/20 | 0.87 |
| ▸ | EGFR | P00533 | 6/20 | 0.83 |
| ▸ | MET | P08581 | 3/20 | 0.83 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.83 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.83 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.83 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.83 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.83 |
| ▸ | AURKA | O14965 | 2/20 | 0.83 |
| ▸ | NUAK1 | O60285 | 2/20 | 0.83 |
| ▸ | JAK2 | O60674 | 2/20 | 0.83 |
| ▸ | STK10 | O94804 | 2/20 | 0.83 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.83 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.83 |
| ▸ | ABL1 | P00519 | 2/20 | 0.83 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.83 |
| ▸ | LCK | P06239 | 2/20 | 0.83 |
| ▸ | FYN | P06241 | 2/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12781751 | 0.94 | ALK (0.85) | ALKINSRIGF1REGFRMET | |
| SCHEMBL12781316 | 0.94 | ALK (0.77) | ALKINSRIGF1REGFRMET | |
| SCHEMBL12780998 | 0.93 | EGFR (0.77) | ALKINSRIGF1REGFRMET | |
| SCHEMBL26451583 | 0.93 | EGFR (0.77) | ALKINSRIGF1REGFRMET | |
| SCHEMBL30123962 | 0.93 | EGFR (0.77) | ALKINSRIGF1REGFRMET | |
| Tae-684 SCHEMBL29641017 | 0.91 | ALK (1.00) | ALKINSRIGF1REGFRMET | |
| Tae-684 SCHEMBL282775 | 0.91 | ALK (1.00) | ALKINSRIGF1REGFRMET | |
| SCHEMBL4100628 | 0.90 | ALK (0.81) | ALKINSRIGF1REGFRMET | |
| SCHEMBL2822748 | 0.89 | ALK (0.81) | ALKINSRIGF1REGFRMET | |
| SCHEMBL26906628 | 0.89 | ALK (0.75) | ALKINSRIGF1REGFRMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228458-A1 | PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME | THERAPEX CO., LTD. (KR) | 2024-07-11 | — | — | US | claimed |
| EP-4286376-A1 | PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME | Therapex Co., Ltd. (KR) | 2023-12-06 | — | — | EP | claimed |
| CN-117120424-A | Pyrimidine derivatives having protein kinase inhibitory activity and therapeutic combinations comprising the same | 泰拉佩克斯有限公司 | 2023-11-24 | — | — | CN | claimed |
| WO-2022211573-A1 | PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME | 주식회사 테라펙스 | 2022-10-06 | — | — | WO | claimed |
| US-20240228458-A1 | PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME | THERAPEX CO., LTD. (KR) | 2024-07-11 | — | — | US | disclosed |
| EP-4286376-A1 | PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME | Therapex Co., Ltd. (KR) | 2023-12-06 | — | — | EP | disclosed |
| CN-117120424-A | Pyrimidine derivatives having protein kinase inhibitory activity and therapeutic combinations comprising the same | 泰拉佩克斯有限公司 | 2023-11-24 | — | — | CN | disclosed |
| WO-2022211573-A1 | PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME | 주식회사 테라펙스 | 2022-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228458-A1 | PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME | EGFR, ERBB2, ERBB3 | ALK 120/4885INSR 607/4885IGF1R 592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.